CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Condition: Oropharyngeal Cancer Interventions: Drug: Cisplatin; Drug: Durvalumab; Procedure: Radiotherapy; Procedure: Dose-escalated radiotherapy Sponsors: University of Birmingham; AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials